Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 10/20 | 0.81 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.81 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.81 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.57 |
| ▸ | GLB1 | P16278 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9481013 | 0.98 | GNAO1 (0.85) | GNAO1GNAI3GNAI1SPHK1GLB1 | |
| Dimethylamine SCHEMBL6943947 | 0.94 | GNAO1 (0.72) | GNAO1GNAI3GNAI1SPHK1 | |
| SCHEMBL595977 | 0.93 | GNAO1 (0.92) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL8168253 | 0.92 | GNAO1 (0.70) | GNAO1GNAI3GNAI1SPHK1 | |
| SCHEMBL19779489 | 0.91 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL4249763 | 0.91 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL5852136 | 0.91 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| Diethylamine SCHEMBL6946338 | 0.90 | GNAO1 (0.68) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL6944193 | 0.89 | GNAO1 (0.66) | GNAO1GNAI3GNAI1SPHK1 | |
| SCHEMBL6943797 | 0.89 | GNAO1 (0.66) | GNAO1GNAI3GNAI1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395889-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| WO-2023034833-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| CN-109336872-A | One kind has the preparation of the gathering induced luminescence material of light stability | 天集化工助剂（沧州）有限公司 | 2019-02-15 | — | — | CN | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-9771330-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-09-26 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9409122-B2 | Gas capture process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-08-09 | — | — | US | disclosed |
| EP-2978752-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| US-6096746-A | Indazole compound containing a monocyclic amine structure | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5945434-A | TREATMENT OF GASTROINTESTINAL DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0829474-A1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5498628-A | ANTIPSYCHOTIC, PSYCHOSTIMULATORY, ANTIAUTISTIC, ANTIDEPRESSANT AND HYPOTENSIVE AGENTS, PARKINSON'S DISEASE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-03-12 | — | — | US | disclosed |
| US-5438064-A | For suppressing the binding of bradykinins to pain receptors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-08-01 | — | — | US | disclosed |
| US-5212182-A | Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics | AMERICAN HOME PRODUCTS CORPOORATION (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0539281-A1 | New naphthamides, process for their preparation and their application in the therapeutical field | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-04-28 | — | — | EP | disclosed |
| US-3933829-A | 4-Aminoquinoline derivatives | JOHN WYETH & BROTHER LIMITED (EN) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | GNAO1 3168/4885GNAI3 2162/4885GNAI1 2106/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | GNAO1 3168/4885GNAI3 2162/4885GNAI1 2106/4885 |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | GNAO1 4319/4885GNAI3 3618/4885GNAI1 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.